Sublingual nifedipine in human pregnancy

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 5, 1997, Pages 538-542

  Gallery, E D M ^a,b   Gyory A Z ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Hypertension; Nifedipine; Pregnancy

Indexed keywords

HYDRALAZINE; LABETALOL; METHYLDOPA; NIFEDIPINE; OXPRENOLOL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FETUS OUTCOME; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0030832729     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb00961.x     Document Type: Article

References (19)

1. Gallery EDM. Chronic and secondary hypertension. In: Rubin PC (Ed). Handbook of hypertension. Vol 10 (Hypertension in pregnancy). Amsterdam, New York, Oxford: Elsevier, 1988; 11: 202-22.
2. ASSHP working party (Brown MA, Gallery EDM, Gatt SP, Leslie G, Robinson J). Management of hypertension in pregnancy. Summary of consensus statement of Australasian Society for the Study of Hypertension in Pregnancy. Med JAust 1993; 158: 700-2.
3. Barr PA, Gallery EDM. Effect of diazoxide on the antepartum cardiotocograph in severe pregnancy-associated hypertension. Aust NZ J Obstet Gynaecol 1981; 21: 11-5.
4. Walters BNJ, Redman CWG. Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine. Br J Obstet Gynaecol 1984; 91: 33-6.
5. Rubin P, Butters L, McCabe R. Nifedipine and platelets in pre-eclampsia. Am J Hypertension 1988; 1: 175-7.
6. Martins-Costa S et al. Randomised, controlled trial of hydralazine versus nifedipine in pre-eclamptic women with acute hypertension. Clin Exper Hypertension in Pregnancy 1992; 11: 25-44.
7. Buring JE et al. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. J Am Med Assoc 1995; 274: 654-5.
8. Opie LH et al. Nifedipine and mortality. Grave defects in the Dossier. Circulation 1995; 92: 1068-73.
9. Epstein M. Calcium antagonists: still appropriate as first line antihypertensive agents. Am J Hypertension 1996; 9: 110-21.
10. Furberg CD et al. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
11. Psaty BM et al. The risk of myocardial infarction associated with antihypertensive drug therapies. J Am Med Assoc 1995; 274: 620-5.
12. Gallery EDM, Ross MR, Gyory AZ. Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyl dopa. Br Med J 1985; 291: 563-6.
13. Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy-induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993; 100: 959-61.
14. Scardo JA, Vermillion ST, Hogg BB, Newman RB. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1996; 175: 336-40.
15. Visser W, Wallenburg HCS. A comparison between haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre-eclampsia. J Hypertension 1995; 13: 791-5.
16. Fenakel K, Fenakel G et al. Nifedipine in the treatment of severe pre-eclampsia. Obstet Gynecol 1991; 77: 331-7.
17. Walss Rodriguez RJ, Flores Padilla LM. Management of severe preeclampsia/eclampsia: comparison between nifedipine and hydralazine as antihypertensive agents. Ginecol Obstet Mex 1993; 61: 76-9.
18. McAllister RG. Kinetics and dynamics of nifedipine after oral and sublingual doses. Am J Med 1986; 81: 2-5.
19. Waisman GD et al. Magnesium plus nifedipine: potentiation of hypotensive effect in pre-eclampsia. Am J Obstet Gynecol 1988; 159: 308-9.